Evaluation of a Web-Based Self-Management Program for Patients With Cardiovascular Disease: Explorative Randomized Controlled Trial

Marscha M Engelen¹, MSc; Sandra van Dulmen²,³,⁴, PhD; Saskia Puijk-Hekman¹, MSc; Hester Vermeulen¹,⁵, PhD; Maria WG Nijhuis-van der Sanden¹, PhD; Sebastian JH Bredie⁶, MD, PhD; Betsie GI van Gaal¹,⁵, PhD

¹IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands
²Department of Primary and Community Care, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands
³Netherlands Institute for Health Services Research, Utrecht, Netherlands
⁴Faculty of Health and Social Sciences, University of South-Eastern Norway, Drammen, Norway
⁵Institute of Nursing, Faculty of Health and Social Studies, HAN University of Applied Sciences, Nijmegen, Netherlands
⁶Department of Internal Medicine, Radboud university medical center, Nijmegen, Netherlands

Corresponding Author:
Marscha M Engelen, MSc
IQ Healthcare
Radboud Institute for Health Sciences
Radboud university medical center
PO Box 9101
Nijmegen
Netherlands
Phone: 31 654272129
Email: marscha.engelen@radboudumc.nl

Abstract

Background: Web-based self-management programs have the potential to support patients with cardiovascular disease (CVD) in their self-management (eg, by focusing on behavior change and improving physical activity). The intervention mapping framework was used to develop a web-based program called Vascular View. The Vascular View program contained 6 modules (coping with CVD, setting boundaries, lifestyle, healthy nutrition, being physically active, interaction with health professionals) aiming to increase self-management behavior by tailoring to the perceived problems and (support) needs of patients after CVD.

Objective: The aim was to test the effectiveness of Vascular View before embarking on a full-scale randomized clinical trial (RCT) by evaluating the potential effectiveness and effect sizes of the Vascular View program and identifying outcome measures most likely to capture the potential benefits.

Methods: An explorative RCT was performed. Both control and intervention groups received care as usual and, in addition, the intervention group received 12 months of access to a web-based self-management program. Assessment occurred at baseline, 6 months, and 12 months. Outcome measures included general patient-reported outcome measurements: Illness Perception Questionnaire (IPQ), Rand-36, Patient Activation Measure, and patient self-efficacy. Module-specific patient-reported outcome measurements were Beliefs about Medicines Questionnaire, International Physical Activity Questionnaire, Dutch Healthy Diet Index, Fagerström Test for Nicotine Dependence (FTND), Alcohol Use Disorders Identification Test, and Perceived Efficacy in Patient-Physician Interaction. Linear mixed models for repeated measures using intention-to-treat and per-protocol analysis were applied to study differences between the patients in the intervention and control groups. Floor and ceiling effects were explored to give insight into the outcome measures most likely to capture the potential benefits.

Results: A total of 105 patients in the control group and 103 patients in the intervention group participated in the study. A positive direction of change between baseline and 12 months was shown for most outcome measurements in favor of the intervention group, of which 2 out of 10 outcomes showed a significant effect: attribution of cause of the disease to risk factors and immunity factors (IPQ) and dependency of nicotine (FTND). Floor and ceiling effects were seen in the IPQ, Rand-36, and the self-efficacy questionnaire.
Conclusions: No conclusion for the efficacy of the Vascular View program or selection of outcome measurements can be taken yet. A process evaluation will be conducted to gain thorough insight into the working elements of the program, patient needs in eHealth, and the use of the program by patients. This can determine for whom web-based self-management programs will work and help to adapt the program.

Trial Registration: Dutch Trial Register NTR5412; https://www.trialregister.nl/trial/5303

International Registered Report Identifier (IRRID): RR2-10.2196/resprot.6352

(J Med Internet Res 2020;22(7):e17422) doi: 10.2196/17422

KEYWORDS

explorative randomized controlled trial; cardiovascular diseases; self-management; eHealth support programs; internet; lifestyle; nursing

Introduction

Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and survivors of CVD are at high risk for a secondary CVD event [1]. Prevention of secondary CVD events can be influenced by focusing on the interaction of behavioral risk factors (lifestyle components), metabolic risk factors (hypertension, high blood glucose levels, raised blood lipids, and overweight), and other risk factors (eg, advancing age, sex, stress, and depression) [1]. Managing these factors poses high demands on patient self-management skills. Despite support from health care professionals, patients have trouble managing their CVD and its consequences in daily life themselves [2]; they experience disease-related problems such as dealing with the symptoms, treatment, physical and psychological consequences, and recommended lifestyle changes.

Self-management of chronic illness has been widely recognized as a way to support patients in achieving the best possible quality of life with their chronic condition [3,4]. Secondary prevention programs targeting self-management through risk factors and (lifestyle) behavior change have been associated with reduced mortality, reduction of repeated cardiac events, and improved health-related quality of life [5,6]. However, attendance rate in cardiac rehabilitation programs remains less than 50% worldwide [7,8] due to barriers like lack of transportation, embarrassment of participation, a dislike of group environments, and work or domestic commitments [9,10]. The use of web-based self-management programs could be a remedy to these barriers, since these programs have the potential to reach a large group of patients and diminish barriers because of the possibility of accessing programs anytime and anywhere and providing anonymity. Buys and colleagues [11] found that patients with CVD showed a high interest in support through the internet (77%) and mobile phones (68%).

Recent systematic reviews have shown the high potential of electronic health (eHealth) interventions for CVD prevention [12-15]. Widmer and colleagues [14] demonstrated significant reduction on CVD outcomes due to digital health interventions (relative risk –0.61, 95% CI 0.46-0.80; P<.001; I²=22%). Another systematic review studied behavioral change by using mobile health interventions: studies aiming to improve physical activity (n=2) or medication adherence (n=3) showed positive effects, but no effects were seen in studies aiming to decrease smoking (n=1) or change diets (n=1) [12]. Duff and colleagues [15] investigated the use of behavior change techniques (BCTs) in eHealth interventions for improving physical activity for patients with CVD; 8 of the 15 interventions showed significant improvements, while in 5 of the 15 studies the intervention group scored equal to the control group.

Not all studies recognize the potential of eHealth interventions, and demonstrate more questionable results. Hamine and colleagues [16] evaluated the effectiveness of mobile health (mHealth) interventions in supporting adherence of patients to chronic disease management (including CVD). Out of 41 randomized controlled trials (RCTs) that measured the effects of mHealth interventions on disease-specific clinical outcomes, significant improvements between groups were reported in only 16 studies (39%). Specific for cardiovascular risk factors, another review showed that the use of multiple modifiable internet lifestyle interventions in primary or secondary care is not superior to usual care [17]. Although 4 out of 9 studies demonstrated significant improvement in various risk factors, clinical relevance of these differences is questionable [17]. Inconsistent evidence is often due to limitations in the intervention and research design and a lack of power in the studies [18]. Limitations like small sample sizes, unclear description of intervention characteristics, short duration, and selection bias were noted in review studies [12,13].

To reduce the risk of limitations, we used the intervention mapping (IM) framework to develop a comprehensive, multicomponent web-based self-management program for patients with CVD called Vascular View (Vaat in Zicht in Dutch). IM contains 6 steps to design, implement, and evaluate an intervention based on the foundation of theoretical, empirical, and practical information [19]. The program Vascular View aims to increase self-management behavior tailored to the perceived problems and (support) needs of patients after CVD diagnosis [20]. Each of the 6 modules has a specific goal based on determinants of the 1-change model [21]. For each of these selected determinants, BCTs were selected [22]. A detailed description of the development and content of Vascular View has been described elsewhere [20].

The last step of IM (step 6) is evaluation. This paper describes the testing of the effectiveness of Vascular View before embarking on a full-scale RCT. This explorative RCT study in patients with CVD aims to evaluate the potential effectiveness and effect sizes of the Vascular View program on 10 patient outcome measures and identify the outcome measures most
likely to capture the potential benefits of the Vascular View program.

**Methods**

**Design**

An explorative RCT was conducted at four outpatient clinics (cardiology, internal medicine, neurology, and vascular surgery) at Radboud University Medical Center in the Netherlands. To explore the efficacy of the web-based self-management program and identify suitable outcome measures, questionnaire data of patients allocated to the intervention and control groups were compared at 6 and 12 months after baseline on 10 outcome measurements related to the performance objectives of the intervention. Table 1 shows the modules, performance objectives, and related outcomes of the intervention. Since all outcomes are targeted through the intervention, positive effects are expected on all outcomes. The trial is registered in the Dutch Trial Register [NTR5412]. The medical ethics committee of Arnhem-Nijmegen in the Netherlands approved this study (registration number: 2015/1908).

Table 1. Modules, performance objectives, determinants, and related outcomes of the intervention.

| Module | Performance objectives | Determinants | Module-specific outcomes |
|--------|------------------------|--------------|-------------------------|
| Coping with CVD* (3 sessions) | Patients have insight into CVD and accompanying symptoms and consequences. Patients cope with CVD and accompanying symptoms and consequences. Patients cope with (changed) sexuality and intimacy. Patients cope with stress in daily life. Patients cope with fear and emotions related to CVD. Patients cope with pain related to CVD. Patients adhere to medication instructions. | Knowledge, awareness, risk perception, attitude, self-efficacy, subjective norm, intention, action plans | BMQ\(^b\) Self-efficacy (subscale: acceptance) |
| Setting boundaries in daily life (4 sessions) | Patients set boundaries. Patients adapt to changed circumstances. Patients ask for support from partner, relatives, and social environment. Patients cope with changed roles in family, job, and/or society. Patients are able to resume activities within their own possibilities. | Knowledge; awareness, attitude, self-efficacy, subjective norm | Self-efficacy (subscale: social environment), Self-efficacy (subscale: setting boundaries) |
| Lifestyle (4 sessions) | Patients refrain from tobacco use. Patients refrain from (harmful) alcohol use. | Knowledge, awareness, attitude, self-efficacy, subjective norm, intention, habits, skills | FTND\(^c\), AUDIT\(^d\), Self-efficacy (subscale: smoking), Self-efficacy (subscale: alcohol) |
| Healthy nutrition (3 sessions) | Patients eat healthy. | Knowledge, awareness, attitude, self-efficacy, subjective norm, intention, habits, skills | DHD\(^e\), Self-efficacy (subscale: diet) |
| Being physically active in a healthy way (3 sessions) | Patients are physically active. | Knowledge, awareness, attitude, self-efficacy, subjective norm, intention, habits, skills | IPAQ\(^f\), Self-efficacy (subscale: physical activity) |
| Interaction with health professionals (4 sessions) | Patients interact with health professionals. | Knowledge, awareness, attitude, self-efficacy, subjective norm | PEPPI-5\(^g\), Self-efficacy (subscale interaction) |

\(^a\)CVD: cardiovascular disease.  
\(^b\)BMQ: Beliefs about Medicine Questionnaire.  
\(^c\)FTND: Fagerstrom Test for Nicotine Dependence.  
\(^d\)AUDIT: Alcohol Use Disorders Identification Test.  
\(^e\)DHD: Dutch Health Diet Index.  
\(^f\)IPAQ: International Physical Activity Questionnaire.  
\(^g\)PEPPI-5: Perceived Efficacy in Patient-Physician Interactions.
Participants
In the third quarter of 2015, 600 consecutive patients who had visited the outpatient clinic because of an established cardiovascular event were invited by the treating medical specialist to participate in this study. Inclusion criteria were (1) a cardiovascular disease (myocardial infarction, cerebrovascular disease [stroke included], peripheral artery disease, or combination); (2) a CVD event within 2 months to 1 year before start of the study; (3) aged 18 years or older; (4) able to read and understand Dutch; and (5) have access to a computer, internet, and an email account. Patients with a psychiatric disorder were excluded. Patients received information about the content and aim of the study, a short questionnaire to assess the inclusion criteria, and an informed consent form from the medical specialist via postal letter. Patients were asked to sign and return the informed consent form and completed questionnaire to the researcher (ME). When patients agreed to participate and were eligible, they received an invitation to complete the online questionnaire baseline data collection.

Randomization
Randomization took place after the baseline measurement and was stratified for four patient diagnoses: myocardial infarction, cerebrovascular disease (stroke included), peripheral artery disease, and aneurysm. The most recent diagnosis was used in randomization for patients with comorbidity in CVD. A blinded and independent statistician executed the randomization using SAS version 9.4 (SAS Institute Inc), which is an automated randomization program. The researcher (ME) informed patients about their assignment to control or intervention group. All patients in both groups continued with their care as usual: regular visits, treatment at the outpatient clinics, and standardized cardiovascular risk management, which contained an evaluation of cardiovascular risk factors, including feedback to optimize lifestyle. In addition to the care as usual, patients in the intervention group received 12 months access to the intervention (October 2015 until October 2016) directly after randomization.

Intervention
The Vascular View program was systematically developed in collaboration with CVD patients and health care professionals [20]. By defining performance and change objectives in conformity with the IM steps [19], 6 topics were distinguished and incorporated into the modules included in Vascular View: (1) coping with CVD, (2) setting boundaries in daily life, (3) lifestyle in general with specific attention to tobacco and harmful alcohol use, (4) healthy nutrition, (5) being physically active in a healthy way, and (6) interaction with health care professionals. Moreover, patients had access to two diaries (exercise and alcohol use, (4) healthy nutrition, (5) being physically active in a healthy way, and (6) interaction with health care professionals. The Patient Activation Measure (PAM-13), which includes 13 items on a 5-point Likert scale measuring four dimensions: psychological attributions, risk factors, immunity, and accident or chance. A higher score indicates a higher level of attribution to the dimension [23].

General Patient-Reported Outcome Measurements
Patient’s illness attributions were assessed by the “causes of my illness” section on the IPQ. It contains 18 items measured on a 5-point Likert scale measuring four dimensions: physical functioning, social functioning, physical role limitations, emotional role limitations, mental health, vitality, pain, and general health perception [24]. The subscales of patient’s general health state was measured with the Rand-36, consisting of 36 items measuring 8 dimensions: physical functioning, social functioning, physical role limitations, emotional role limitations, mental health, vitality, pain, and general health perception [24]. The subscales of patient’s general health status was measured with the Rand-36, consisting of 36 items measuring 8 dimensions: physical functioning, social functioning, physical role limitations, emotional role limitations, mental health, vitality, pain, and general health perception [24]. The subscales of patient’s general health status was measured with the Rand-36, consisting of 36 items measuring 8 dimensions: physical functioning, social functioning, physical role limitations, emotional role limitations, mental health, vitality, pain, and general health perception [24]. The subscales of patient’s general health status was measured with the Rand-36, consisting of 36 items measuring 8 dimensions: physical functioning, social functioning, physical role limitations, emotional role limitations, mental health, vitality, pain, and general health perception [24]. The subscales of patient’s general health status was measured with the Rand-36, consisting of 36 items measuring 8 dimensions: physical functioning, social functioning, physical role limitations, emotional role limitations, mental health, vitality, pain, and general health perception [24].

The Patient Activation Measure (PAM-13), which includes statements about an individual’s knowledge, confidence, and skills for self-management of their chronic illness behavior and the level of activation, was used to measure participants’ self-management ability. The PAM-13 includes 13 items on a 5-point scale with a higher score indicating a higher level of patient activation [25,26]. No validated questionnaire was available that corresponded to the aims of the intervention; therefore, patient’s self-efficacy was assessed by the PAM-13.

Measurements and Outcomes
Baseline Characteristics
All patients who completed the baseline questionnaire between August 2015 and October 2015 received a questionnaire after 6 months (T1) and after 12 months (T2). At baseline, the following demographic and disease-related characteristics were collected: age, sex, educational level, work participation, cultural background, diagnosis and comorbidity, duration of illness, body weight, height, computer use, and experience with rehabilitation programs. Patient-reported outcome measurements were assessed at baseline and during follow-ups (T1 and T2). These outcomes could be distinguished in generic and module-specific outcomes (Table 1). The great amount of outcomes resulted in a long questionnaire with a great demand of time on participants. Therefore, the questionnaire at T1 was shortened by omitting two questionnaires: the Illness Perception Questionnaire (IPQ) and Rand-36. When patients preferred a paper questionnaire, a version was sent by post.

Table 1. Measurements and Outcomes

Baseline Characteristics

General Patient-Reported Outcome Measurements

The Project Description Measure (PAM-13), which includes statements about an individual’s knowledge, confidence, and skills for self-management of their chronic illness behavior and the level of activation, was used to measure participants’ self-management ability. The PAM-13 includes 13 items on a 5-point scale with a higher score indicating a higher level of patient activation [25,26]. No validated questionnaire was available that corresponded to the aims of the intervention; therefore, patient’s self-efficacy was assessed by the PAM-13.
was measured with a self-developed questionnaire (see Multimedia Appendix 1 for an overview of the scales and examples of items). The aim of this questionnaire was to measure how confident patients felt about self-managing CVD based on the performance objectives and corresponding determinants (step 2 of the IM framework). Four patients from the expert group, who were involved in the development of the Vascular View-program [20], were asked to participate in the Think Aloud procedure, a technique used to evaluate the questionnaire [27]. The final questionnaire included 26 items measuring 8 subscales. The items were scored on a 4-point scale with a higher score indicating a higher level of confidence about self-managing CVD. For each subscale, Cronbach was calculated using the baseline, 6-month, and 12-month data of both groups (control and intervention). Each subscale is related to a module in the Vascular View program (see Table 1): acceptance (Cronbach =.81), social environment (Cronbach =.87), interaction with professionals (Cronbach =.85), physical activity (Cronbach =.83), diet (Cronbach =.84), smoking (Cronbach =.83), alcohol (Cronbach =.90), and setting boundaries (Cronbach =.78).

**Module-Specific Patient-Reported Outcome Measurements**

To measure patient attitudes toward their prescribed medicine, the first scale on the Beliefs about Medicines Questionnaire (BMQ) was used, which contains 10 items on a 5-point Likert scale. Two subscales (concerns and necessity) each contained 5 items that summed up to a scale score. A higher score reflects higher levels of concerns or feelings of necessity concerning the prescribed medicine [28,29].

Patient physical activity was measured with the International Physical Activity Questionnaire (IPAQ, short version) [30]. The IPAQ contains 7 questions divided in 3 subscales: walking, moderate intensity activity, and vigorous intensity activity. These subscales are described in minutes per week.

The Dutch Healthy Diet Index is a 34-item questionnaire to estimate adherence to the 2006 Dutch guidelines for a healthy diet, containing 8 components: vegetables, fruit, dietary fiber, fish, saturated fats, trans fats, natrium, and alcohol. Per component the score ranges between 0 and 10, resulting in a total score between 0 (no adherence) and 80 (complete adherence) [31].

Patient tobacco dependence was measured with the Fagerström Test for Nicotine Dependence. This questionnaire consists of 6 items resulting in a total score between 1 and 10, in which a higher score reflects more dependence of nicotine [32].

Alcohol use was measured by the 3-item Alcohol Use Disorders Identification Test with a total score from 0 to 12. A score of 5 or higher indicates the possibility of increasing risk and higher risk of alcohol drinking [33].

Patient interaction with health care professionals was measured with the Perceived Efficacy in Patient-Physician Interaction, which contains 5 items on a 5-point Likert scale that are summed to determine the total score. A higher score reflects more confidence of the patient in interactions with their physician [34,35].

**Biomedical Measurements**

Electronic patient dossiers were searched for biomedical data on two time points: April 2015 to December 2015 (baseline measurement) and April 2016 to March 2017 (12-month measurement). The search of biomedical data included weight, BMI, systolic and diastolic blood pressure, total cholesterol, low-density lipoprotein–cholesterol, high-density lipoprotein–cholesterol, triglycerides, and non–high-density lipoprotein–cholesterol.

**Statistical Analysis**

For explorative RCTs such as this, sample sizes are not calculated based on formal power analyses. Therefore, a sample size of 200 patients was chosen for this trial, which was considered a sufficient size for a representation of the relevant variation in the target group. All quantitative data were analyzed using SPSS Statistics version 25 (IBM Corporation). Descriptive analyses were used to describe the control and intervention groups at baseline. The differences between patient characteristics in the intervention and control group were tested using t tests and chi-square tests. A P value of <.05 was determined as statistically significant in all analyses.

A linear mixed-model analysis with repeated measures on intention-to-treat (ITT) basis was used to determine the differences in outcome measures between the intervention and control group. In this model, the outcomes were the dependent variables and the patient was the random factor. The fixed factors were group (intervention/control) and time and the interaction between time and group. This method automatically uses the missing at random assumption to handle missing data.

Subsequently, a per-protocol analysis (PPA) was performed to compare the control and intervention group with only those patients who completed the treatment originally allocated. Patients in the control group were included if they completed the questionnaire at baseline and 6 and 12 months. Patients in the intervention group were included if they completed the questionnaire at baseline and 6 and 12 months and used Vascular View at least once. Moreover, the same tests and linear mixed-model analyses were used as described in the ITT section.

**Identifying Outcome Measures**

To identify outcome measures most likely to capture the potential benefits, floor and ceiling effects were explored for all outcome measurements using Likert scales at baseline. A floor effect indicates that most of the participants score near the minimum score and a ceiling effect indicates that most participants score near the maximum score on a questionnaire.

In this calculation, we considered floor and ceiling effects exceeding 20% to be significant [36]. Thereby, spaghetti plots were used to analyze the changes between T0 and T2 for all individuals.

**Results**

**Participants**

In total, 600 patients were eligible and invited by the medical specialist. Of these, 238 patients expressed interest, and 208
(87.4%) participated in the study (see Figure 1). Of the 30 patients who were not included, 3 did not meet the inclusion criteria, 6 declined, and 21 did not respond to the invitation. The 208 participating patients were randomized to the intervention (n=103) or control group (n=105) and stratified by CVD diagnosis. Two intervention group patients completed the baseline questionnaire but declined to participate in the intervention. At T1, 86 patients in the intervention group and 103 in the control group completed the questionnaire. At T2, 78 patients in the intervention group and 96 in the control group completed the questionnaire. More intervention group patients (25/103, 24.3%) compared with control group patients (9/105, 8.6%) were lost to follow-up.

All patients in the intervention group (n=101) had access to Vascular View, of which 37.6% (38/101) did not visit the program or only once, 27.7% (28/101) visited the program 2 to 20 times, and 34.7% (35/101) visited the program more than 20 times. The range of visits was between 1 and 43 visits per participant.

Figure 1. Flowchart of Vascular View study.

**Assessed for eligibility (n= 600)**
- Did not meet the inclusion criteria (n= 77)
- Declined to participate (n=126)
  - Unknown (n=32); no need (n=58); Private (n=3); Deceased (n=4); Other diagnosis (n=5)
  - Too great a burden (n=23); Objections (n=4)
- No response (n=157)

**Invited for baseline (n= 238)**
- Did not meet the inclusion criteria (n=3)
- Declined to participate (n=6)
- Not responded (n=21)

**Randomised (n= 208)**

**Intervention group (n = 103)**
- Received intervention (n=101)
- Declined to start due to high level of burden (n=2)

**Control group (n = 105)**
- Received care as usual (n = 105)

**Lost to follow-up (n=25)**
- Reasons: Deceased (n=1); Declined (n=13); Not responded (n=11)

**Lost to follow-up (n=9)**
- Reasons: Deceased (n=1); Declined (n=1); Not responded (n=7)

**Analysed (n=103)**

**Analysed (n=105)**
Outcomes of the Intention-To-Treat Analysis

Baseline Characteristics of Patients

Demographic and disease-related characteristics at baseline were compared for the control and intervention group, as shown in Table 2. The mean age of the patients in the intervention group was 63.3 (SD 10.0) years and 63.7 (SD 9.8) years in the control group. Both groups had more men than women: 69 men in the control and 73 in the intervention group. There were no statistically significant differences between the control and intervention group.

Table 2. Intention-to-treat analysis: patient characteristics at baseline.

| Characteristics                     | Control (n=105) | Intervention (n=103) |
|-------------------------------------|----------------|----------------------|
| Sex (male), n (%)                   | 69 (66.0)      | 73 (71.0)            |
| Age in years, mean (SD)             | 63.7 (9.8)     | 63.3 (10.0)          |
| BMI (kg/m^2), mean (SD)             | 28.4 (4.8)     | 27.2 (4.9)           |
| Disease duration, mean (SD)         | 4.9 (8.2)      | 4.3 (7.7)            |
| **Education level, n (%)**          |                |                      |
| Low                                 | 24 (22.9)      | 17 (16.5)            |
| Intermediate                        | 39 (37.1)      | 34 (33.0)            |
| High                                | 42 (40.0)      | 52 (50.5)            |
| Work participation (yes), n (%)     | 35 (33.3)      | 40 (38.8)            |
| **Diagnosis group, n (%)**          |                |                      |
| Myocardial infarction               | 57 (54.3)      | 58 (56.3)            |
| Cerebrovascular disease (stroke included) | 35 (33.3) | 33 (32.0)          |
| Peripheral artery disease           | 13 (12.4)      | 12 (11.7)            |
| Comorbidity within CVD^a (yes), n (%) | 21 (20.0)   | 18 (17.5)            |
| Comorbidity, other (yes), n (%)     | 32 (30.5)      | 30 (32.0)            |
| Cultural background (Dutch), n (%)  | 101 (96.2)     | 100 (97.1)           |

^aCVD: cardiovascular disease.

Biomedical Measurements

An overview of the mean scores and standard deviations of patients in the intervention and control group at baseline and after 12 months is presented in Table 3. No statistically significant differences were found between the control and intervention group.

The biomedical data show a high level of missing values in both the control and intervention group. For example, triglycerides show a large group of missing values: 45% of values are gathered at T2 compared with T0.
Table 3. Biometrics of control and intervention group.

| Biometrics            | Control group (n=105) | Intervention group (n=103) |
|-----------------------|-----------------------|---------------------------|
|                       | T0a                   | T2b                       | T0                      | T2                      |
|                       | n  mean (SD)          | n  mean (SD)              | n  mean (SD)            | n  mean (SD)            |
| Weight (kg)           | 81  86 (16)           | 56  90 (20)               | 84  85 (15)             | 46  86 (15)             |
| BMI (kg/m²)           | 81  28.3 (4.5)        | 56  29.3 (5.3)            | 83  27.3 (4.0)          | 46  27.5 (4.3)          |
| Systolic BP<sup>c</sup> (mm Hg) | 96  135 (19)        | 84  135 (15)              | 94  135 (17)            | 68  134 (18)            |
| Diastolic BP (mm Hg)  | 96  79 (10)           | 84  77 (11)               | 94  79 (9)              | 68  77 (10)             |
| Total cholesterol     | 87  4.2 (1.1)         | 55  4.0 (0.9)             | 83  4.3 (1.2)           | 47  4.2 (1.1)           |
| LDL-C<sup>d</sup>     | 67  2.2 (0.8)         | 33  2.1 (0.8)             | 65  2.3 (0.8)           | 29  2.2 (0.9)           |
| HDL-C<sup>e</sup>     | 87  1.2 (0.3)         | 54  1.2 (0.4)             | 83  1.1 (0.3)           | 47  1.2 (0.3)           |
| Triglycerides         | 71  1.9 (1.6)         | 33  1.8 (1.4)             | 69  1.9 (1.2)           | 30  1.9 (1.3)           |
| non–HDL-C             | 87  3.0 (1.1)         | 53  2.7 (0.9)             | 82  3.2 (1.1)           | 46  3.0 (1.1)           |

<sup>a</sup>T0: baseline.  
<sup>b</sup>T2: 12 months.  
<sup>c</sup>BP: blood pressure.  
<sup>d</sup>LDL-C: low-density lipoprotein–cholesterol.  
<sup>e</sup>HDL-C: high-density lipoprotein–cholesterol.

Patient Outcome Measurements at Baseline and Follow-Up

Multimedia Appendix 2 provides an overview of the mean scores and standard deviations of outcome measurements of the patients in the intervention and control group at baseline and after 6 and 12 months. At baseline, the intervention group had more patients who smoked (n=13) compared with the control group (n=5), which was a statistically significant difference (mean difference 0.4; \( P=.04 \)). Thereby, patients in the intervention group scored at baseline significantly higher on self-management behavior (PAM-13) compared with patients in the control group (mean difference 4.4; \( P=.03 \)).

The estimated differences and \( P \) values between the intervention and control group after ITT analysis at 6 and 12 months after baseline are presented in Multimedia Appendix 2. Six out of 29 variables in the intervention group and 13 out of 29 in the control group decreased over time. Two questionnaires showed significant effects in favor of the intervention group. First, the IPQ scores showed that intervention group patients attributed the cause of their disease more to risk factors and immunity factors after 12 months. Patients in the control group showed a decrease on attribution to risk factors and a small increase on immunity factors. Second, the intervention group showed a statistically significant decrease for the dependency of nicotine after 6 months (–1.55; \( P=.01 \)) and after 12 months (–1.67; \( P=.01 \)) with respect to T0.

Outcomes Per-Protocol Analysis

Baseline Characteristics of Patients

There were no significant between-group differences found in the demographic and disease-related characteristics at baseline for the control and intervention group of the patients following the intervention per protocol (Table 4).
Table 4. Per-protocol analysis: patient characteristics at baseline.

| Characteristics                              | Control (n=95) | Intervention (n=52) |
|----------------------------------------------|---------------|--------------------|
| Sex (male), n (%                           | 62 (65.3)     | 36 (69.2)          |
| Age in years, mean (SD)                     | 63.9 (9.4)    | 61.8 (9.3)         |
| BMI (kg/m²), mean (SD)                      | 28.5 (4.9)    | 27.2 (5.2)         |
| Disease duration, mean (SD)                 | 4.7 (7.9)     | 4.0 (8.2)          |
| **Education level, n (%)**                  |               |                    |
| Low                                          | 23 (24.2)     | 12 (23.1)          |
| Intermediate                                 | 34 (35.8)     | 12 (23.1)          |
| High                                         | 38 (40.0)     | 28 (53.8)          |
| Work participation (yes), n (%)              | 19 (36.5)     | 29 (30.5)          |
| **Diagnosis group, n (%)**                  |               |                    |
| Myocardial infarction                       | 51 (53.7)     | 34 (65.4)          |
| Cerebrovascular disease (stroke included)   | 32 (33.7)     | 14 (26.9)          |
| Peripheral artery disease                   | 12 (12.7)     | 1 (7.7)            |
| Comorbidity within CVD<sup>a</sup>, n (%)    | 19 (20.0)     | 6 (11.5)           |
| Comorbidity, other (yes), n (%)              | 29 (30.5)     | 17 (32.7)          |
| Cultural background (Dutch), n (%)          | 92 (96.8)     | 51 (98.1)          |

<sup>a</sup>CVD: cardiovascular disease.

**Patient Outcome Measurements at Baseline and Follow-Up**

Multimedia Appendix 3 gives an overview of the PPA with mean scores, standard deviations, effect sizes, and P values of outcome measurements of the patients in the intervention and control group at baseline and after 6 and 12 months. At baseline, patients in the intervention group scored significantly higher on self-management behavior (PAM-13) compared with patients in the control group (mean difference 5.6; P=.03). The subscale social environment showed a significantly higher score on self-efficacy for intervention group patients compared with the control group (mean difference 0.2; P=.04) at baseline.

The PPA showed effects on the same outcomes as the ITT analysis. The IPQ scores on risk factors (0.31; P=.02) and immunity factors (0.48; P<.001) showed a statistically significant difference between intervention and control group: the IPQ scores show that after 12 months, patients in the intervention group attributed the cause of their disease more to risk factors and immunity factors. Patients in the control group showed a decrease on attribution to risk factors and no change on immunity factors. Patients in the intervention group decreased the dependency of nicotine significantly toward the control group after 6 months (−1.87; P=.01) and after 12 months (−1.72; P=.02).

**Suitable Outcome Measures**

The percentages of patients scoring 0 (floor effects) or full marks (ceiling effects) on the 10 outcome measures were assessed at baseline. Significant floor effects were seen on the subscales IPQ psychological attributions (22.0%), IPQ immunity (35.3%), and IPQ accident or chance (26.6%). Significant ceiling effects were noticed on the subscales Rand social functioning (29.3%), Rand bodily pain (29.3%), patient self-efficacy with a self-constructed 26-item questionnaire (SE) interaction (26.9%), SE physical activity (33.8%), SE diet (30.9%), SE alcohol (35.2%), and SE setting boundaries (23.7%).

**Discussion**

**Principal Findings**

This explorative RCT aimed to evaluate the potential effectiveness and effect sizes of the Vascular View program on 10 patient outcome measures and identify the outcome measures most likely to capture potential benefits. The evaluation of potential effectiveness of Vascular View showed significant effects for illness attribution and nicotine dependence. At 12 months, patients in the intervention group attributed the cause of their diseases more often to risk factors and immunity factors than patients in the control group. Intervention group patients showed a decrease in nicotine dependency compared with the control group. It should be noted that we are not convinced that this effect was clinically meaningful due to the small number of participants who stopped or decreased smoking and because the effect is partly due to a high dropout of smokers in the intervention group (4 out of 13) compared with no dropout in the control group and one patient in the control group who started smoking after the baseline measure.

Although the other outcomes showed no statistically significant differences between the intervention and control group, there seems to be a positive trend in the improvement of outcome measurements in favor of the intervention group. Overall, we did not expect to find a nonconvincing trend regarding the efficacy of Vascular View, since the theory-based intervention...
was thoroughly designed with patients and health care professionals on the basis of patient support needs according to the IM steps [19]. Furthermore, the outcome measures were selected carefully and in line with the objectives of the intervention. Randomization was successful, and the number of missing values was limited.

To our knowledge, Vascular View is the first web-based self-management program for secondary care patients with CVD that aims to improve so many components and in which patients can decide which modules they want to use. Other (effective) eHealth interventions for CVD prevention focused primarily on one or two risk factors (eg, physical activity [15] and smoking cessation [37]). Results of web-based self-management programs with multiple components in other diseases show comparable results [38-40]. Vascular View tried to guide patients by using a questionnaire to advise them in choosing courses in the welcome module and lifestyle module [20]. However, the large amount of topics might have resulted in an overload of information and subsequently demotivation and minimal use of the program. The lack of efficacy of the Vascular View program is not in line with studies that show the potential of eHealth interventions for secondary prevention of CVD [12-16]. For example, Vascular View addressed patients’ intrinsic processes through the determinants, which is seen as a successful strategy for face-to-face self-management programs [41]. However, it is hard to compare studies on eHealth self-management programs because of the various eHealth approaches and outcome measures available. Review studies show a large diversity in studies, looking at outcome measures, use of eHealth interventions, implementation, etc.

A discrepancy between needed self-management support by patients and provided self-management support by nurses is familiar in health care. Vascular View is an unguided self-management program in which nurses did not discuss the Vascular View program with patients, the program was not part of consultation, and nurses did not encourage patients to continue use of the program. The question should be raised whether use of the intervention should be supported and perhaps even used as a partial replacement of usual care. Providing self-management support is a core task of nurses in outpatient clinics, and patients expect health care professionals to fulfill a comprehensive role [42]. However, nurses seem to experience barriers in discussing all self-management categories (symptom management, treatment, biomedical cardiovascular risk factors, psychosocial consequences, and lifestyle changes). Physical components are often discussed, but psychological components are left behind [43]. Web-based self-management interventions could be a way to improve self-management support by focusing on the patient instead of the health care professional. More research needs to be conducted to determine the balance between support by the nurse and a self-guided self-management program.

Only half of the intervention group (n=51) adhered to the intervention: they completed all questionnaires and used Vascular View once or more often. Moreover, 38% did not use the program or used it only once. Although a previous questionnaire study showed that 77% of patients with CVD were interested in support through the internet [11], it seems to be important to match expectations of patients with the online program [44]. When patient expectations did not line up with the online program, patients refused to complete the measurements and revisit the online program [44]. Three striking differences between patients in the ITT and PPA give insight in the difference between users and nonusers. First, mostly patients with an intermediate education level drop out (difference between ITT and PPA: 9.9%) and a relatively high number of patients with a lower level of education used the program (difference between ITT and PPA: 6.6%). These results are contrary to other research suggesting that lower educational levels are a barrier for eHealth use [45]. Second, the percentage of patients with myocardial infarction is higher in the intervention group of the PPA (65.4%) compared with the ITT (56.3%). This suggests a higher need for self-management support in patients with a myocardial infarction diagnosis. Third, the Vascular View program seems to be more popular in patients scoring higher on patient-related outcomes such as self-management, physical activity, quality of life, diet, nicotine adherence, and alcohol adherence. Improvement is more difficult to achieve in this group.

The second aim was to identify the outcome measures most likely to capture the potential benefits. Most of the chosen outcome measures were likely to capture the potential effect, although floor and ceiling effects were seen in the IPQ, Rand-36, and patient’s self-efficacy questionnaire. Patient’s illness attributions (IPQ) [23] showed a right-skewed distribution, meaning that more than 20% of the patients attributed their disease not to psychological factors, immunity, accident, or chance at all. However, effects after 12 months were seen on the IPQ since the intervention group increased attribution to psychological factors, immunity, and risk factors. In spite of the floor effects, the IPQ is a valuable measurement to give insight in the efficacy of the Vascular View program. A left-skewed distribution was found in 2 subscales of the Rand-36 [24] (social functioning and bodily pain), indicating that more than 20% of the patients already experienced a high quality of life. Since CVD patients show relatively low pain levels and physical symptoms, for future research we suggest an instrument with a higher sensitivity such as the Seattle Angina Questionnaire [46,47]. The self-efficacy questionnaire also showed a left-skewed distribution, suggesting high self-efficacy on interaction, physical activity, diet, alcohol, and setting boundaries. More research should be conducted to determine the reliability and validity of this self-developed questionnaire. To conclude, a more sensitive instrument for quality of life is suggested for future research. All other questionnaires were sensitive to measure change in this population.

Limitations

We believe this explorative RCT has numerous methodological strengths, although some limitations need to be mentioned. First, more patients in the intervention compared with the control group were lost to follow-up. However, we have not established that patients with specific characteristics dropped out. Second, this research was conducted in the outpatient clinic of a university hospital in which high quality of CVD care is already delivered, and therefore it may be harder to achieve improvement. Last, all patients in the outpatient group were...
informed but only the ones who were interested in the study were invited to participate. A limitation is that this might be a biased group because they were probably already interested in self-management.

**Recommendations for Clinical Practice and Research**

For future studies, we recommend further studying patient self-management needs and the possibilities of tailoring eHealth. Although Vascular View was developed using IM on the basis of the support needs of patients with CVD [20], individual participating patients were not asked for their intentions to improve self-management and change their behavior and what kind of support needs they preferred. In our study, patients with higher starting levels (eg, self-management) were more likely to use the program. So, the readiness to change or phase of the disease might be predictors for using the program (and the needed support type). To conclude, to increase use and efficacy of eHealth programs, more insight into characteristics of patients who could benefit from web-based self-management programs is needed. A process evaluation will be conducted and published using the components of Saunders (fidelity, dose, reach, recruitment, and context) to get more insight into the low compliance with and noneffectiveness of the intervention and fine-tune the inclusion criteria. Furthermore, we believe that the program should be embedded in treatment and supplement self-management support provided by nurses. More research needs to be conducted to determine the balance between nurse support and self-guided self-management programs.

**Conclusions**

This study contributes to our understanding of self-management support for patients with CVD using eHealth apps. Although we believe in the potential of the Vascular View program, there is no conclusive evidence for the efficacy. Using an unguided self-management program might not work for everyone, and the program might need to be embedded in health care more firmly. A detailed process evaluation of the program should be conducted to gain thorough insight into the working elements of the program, patient needs in eHealth, and the use of the program by patients. Finally, it should be investigated how Vascular View can be more tailored to the patient needs and become more embedded in treatment.

**Acknowledgments**

This study is funded by ZonMw, the Netherlands Organization for Health Research and Development (520001001). The authors would like to thank the patients with CVD and health care professionals for their contribution in the expert groups.

**Conflicts of Interest**

None declared.

**Multimedia Appendix 1**

Self-efficacy questionnaire.

[DOCX File, 13 KB-Multimedia Appendix 1]

**Multimedia Appendix 2**

Intention-to-treat analysis: mean scores, standard deviation, effect sizes and \( P \) values of the outcome measures.

[DOCX File, 19 KB-Multimedia Appendix 2]

**Multimedia Appendix 3**

Per-protocol analysis: mean scores, standard deviation, effect sizes and \( P \) values of the outcome measures.

[DOCX File, 19 KB-Multimedia Appendix 3]

**Multimedia Appendix 4**

CONSORT-eHEALTH checklist (v.1.6.1).

[PDF File (Adobe PDF File), 2521 KB-Multimedia Appendix 4]

**References**

1. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. World Health Organization. 2011. URL: http://apps.who.int/iris/bitstream/10665/44701/1/9789241564373_eng.pdf?ua=1 [accessed 2020-06-03]
2. Helping people help themselves: a review of the evidence considering whether it is worthwhile to support self-management. The Health Foundation. 2011. URL: https://www.health.org.uk/sites/default/files/HelpingPeopleHelpThemselves.pdf [accessed 2020-06-03]
3. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA 2002 Oct 16;288(15):1909-1914. [Medline: 12377092]
4. Clark NM. Management of chronic disease by patients. Annu Rev Public Health 2003;24:289-313. [doi: 10.1146/annurev.publhealth.24.100901.141021] [Medline: 12415147]
5. Müller-Riemenscneider F, Meinhard C, Damm K, Vauth C, Bockelbrink A, Greiner W, et al. Effectiveness of nonpharmacological secondary prevention of coronary heart disease. Eur J Cardiovasc Prev Rehabil 2010 Dec;17(6):688-700. [doi: 10.1097/HJR.0b013e3283ace95] [Medline: 20458247]

6. Whalley B, Thompson DR, Taylor RS. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Int J Behav Med 2014 Feb;21(1):109-121. [doi: 10.1007/s12529-012-9282-x] [Medline: 23179678]

7. Turk-Adawi KI, Grace SL. Narrative review comparing the benefits of and participation in cardiac rehabilitation in high-, middle- and low-income countries. Heart Lung Circ 2015 May;24(5):510-520. [doi: 10.1016/j.hlc.2014.11.013] [Medline: 25534902]

8. Bjarnason-Wehrens B, Mcgee H, Zwisler A, Pieplo MF, Benzer W, Schmid J, et al. Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. Eur J Cardiovasc Prev Rehabil 2010 Aug;17(4):410-418. [doi: 10.1097/HJR.0b013e32833f4424] [Medline: 20300001]

9. Neubeck L, Redfern J, Fernandez R, Briffa T, Bauman A, Freedman SB. Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review. Eur J Cardiovasc Prev Rehabil 2009 Jun;16(3):281-289. [doi: 10.1097/HJR.0b013e3282ade7a] [Medline: 19407659]

10. Dalal HM, Zawada A, Jolly K, Moxham T, Taylor RS. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. BMJ 2010;340:b5631 [FREE Full text] [Medline: 2085991]

11. Buys R, Claes J, Walsh D, Cornelis N, Moran K, Budts W, et al. Cardiac patients show high interest in technology enabled cardiovascular rehabilitation. BMC Med Inform Decis Mak 2016 Jul 19;16:95 [FREE Full text] [doi: 10.1186/s12911-016-0329-9] [Medline: 27431419]

12. Pfaffli DL, Dobson R, Whittaker R, Maddison R. The effectiveness of mobile-health behaviour change interventions for cardiovascular disease self-management: A systematic review. Eur J Prev Cardiol 2016 May;23(8):801-817. [doi: 10.1177/204748731663462] [Medline: 26490093]

13. Coorey GM, Neubeck L, Mulley J, Redfern J. Effectiveness, acceptability and usefulness of mobile applications for cardiovascular disease self-management: systematic review with meta-synthesis of quantitative and qualitative data. Eur J Prev Cardiol 2018 Mar;25(5):505-521. [doi: 10.1177/2047487317750913] [Medline: 29313363]

14. Widmer RJ, Collins NM, Collins CS, West CP, Lerman LO, Lerman A. Digital health interventions for the prevention of cardiovascular disease: a systematic review and meta-analysis. Mayo Clin Proc 2015 Apr;90(4):469-480. [doi: 10.1016/j.mayocp.2014.12.026] [Medline: 25841251]

15. Duff OM, Walsh DM, Furlong BA, O’Connor NE, Moran KA, Woods CB. Behavior change techniques in physical activity adherence for people with cardiovascular disease: systematic review. J Med Internet Res 2017 Aug 02;19(8):e281 [FREE Full text] [doi: 10.2196/jmir.7782] [Medline: 28786610]

16. Hamine S, Gerth-Guyette E, Faulx D, Green BB, Ginsburg AS. Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review. J Med Internet Res 2015;17(2):e52 [FREE Full text] [doi: 10.2196/jmir.3951] [Medline: 25803266]

17. Veteging IL, Schrijver EJM, Otten RHJ, Nanayakkara PWB. Internet programs targeting multiple lifestyle interventions in primary and secondary care are not superior to usual care alone in improving cardiovascular risk profile: a systematic review. Eur J Intern Med 2014 Jan;25(1):73-81. [doi: 10.1016/j.ejim.2013.08.008] [Medline: 24011771]

18. Ekeland AG, Bowes A, Flottorp S. Effectiveness of telemedicine: a systematic review of reviews. Int J Med Inform 2010 Nov;79(11):736-771. [doi: 10.1016/j.ijmedinf.2010.08.006] [Medline: 20884286]

19. Bartholomew L, Markham C, Ruiter R, Fernandez M, Kok G, Parcel G. Planning Health Promotion Programs: An Intervention Mapping Approach, 4th Edition. San Francisco: Jossey-Bass; 2016.

20. Puijk-Hekman S, van Gaal BG, Bredie SJ, Nijhuis-van der Sanden MW, van Dulmen S. Self-management support program for patients with cardiovascular diseases: user-centered development of the tailored, web-based program vascular view. JMIR Res Protoc 2017 Feb 08;6(2):e18 [FREE Full text] [doi: 10.2196/resprot.6352] [Medline: 28179214]

21. de Vriese H, Kremers SPJ, Smeets S, Brug J, Eijmael K. The effectiveness of tailored feedback and action plans on an intervention addressing multiple health behaviors. Am J Health Promot 2008;22(6):417-425. [doi: 10.4278/ajhp.22.6.417]

22. De Bruin M, Schaalm H, Hospers H. Coding manual for behavioral change techniques. URL: https://osf.io/bsvxc/download [accessed 2020-06-03]

23. Moss-Morris R, Weinman J, Petrie K, Horne R, Cameron L, Buick D. The Revised Illness Perception Questionnaire (IPQ-R). Psychol Health 2002 Jan;17(1):1-16. [doi: 10.1080/08870440290001494]

24. VanderZee KI, Sanderman R, Heyink JW. Psychometric qualities of the RAND 36-Item Health Survey 1.0: a multidimensional measure of general health status. Int J Behav Med 1996;3(2):104-122. [doi: 10.1207/s15327558ijbm0302_2] [Medline: 16250758]

25. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. Health Serv Res 2005 Dec;40(6 Pt 1):1918-1930 [FREE Full text] [doi: 10.1111/j.1475-6773.2005.00438.x] [Medline: 16336556]
26. Rademakers J, Nijman J, Heijmans M, Rijken M. Measuring patient activation in The Netherlands: translation and validation of the American short form Patient Activation Measure (PAM13). BMC Public Health 2012;12:577 [FREE Full text] [doi: 10.1186/1471-2458-12-577] [Medline: 22849664]

27. Fonteyn ME, Kuipers B, Grobe SJ. A description of think aloud method and protocol analysis. Qual Health Res 2016 Jul;3(4):430-441. [doi: 10.1177/10497239166300403]

28. Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999 Dec;47(6):555-567. [Medline: 10661603]

29. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999 Jan;14(1):1-24. [doi: 10.1080/0887044990840731]

30. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003 Aug;35(8):1381-1395. [doi: 10.1249/01.MSS.0000078924.61453.FB] [Medline: 12900694]

31. van Lee L, Feskens EJM, Meijboom S, Hoot van Huysduyven EJC, van’t Veer P, de Vries JHM, et al. Evaluation of a screener to assess diet quality in the Netherlands. Br J Nutr 2016 Feb;115(3):517-526. [doi: 10.1017/S0007114515004705] [Medline: 26628073]

32. Pomerleau CS, Carton SM, Lutzke ML, Flessland KA, Pomerleau OF. Reliability of the Fagerstam Tolerance Questionnaire and the Fagerstam Test for Nicotine Dependence. Addict Behav 1994;19(1):33-39. [Medline: 8197891]

33. Seth P, Glenshaw M, Sabatier JHF, Adams R, Du Preez V, DeLuca N, et al. AUDIT, AUDIT-C, and AUDIT-3: drinking patterns and screening for harmful, hazardous and dependent drinking in Katutura, Namibia. PLoS One 2015;10(3):e0120850 [FREE Full text] [doi: 10.1371/journal.pone.0120850] [Medline: 25799590]

34. Maly RC, Frank JC, Marshall GN, DiMatteo MR, Reuben DB. Perceived efficacy in patient-physician interactions (PEPPI): validation of an instrument in older persons. J Am Geriatr Soc 1998 Jul;46(7):889-894. [Medline: 9670878]

35. ten Klooster PM, Oostveen JCM, Zandbelt LC, Taal E, Drossaert CHC, Harmsen EJ. Further validation of the 5-item Perceived Efficacy in Patient-Physician Interactions (PEPPI-5) scale in patients with osteoarthritis. Patient Educ Couns 2012 Apr;87(1):125-130. [doi: 10.1016/j.pec.2011.07.017] [Medline: 21889864]

36. Hsueh I, Hsieh C. Responsiveness of two upper extremity function instruments for stroke inpatients receiving rehabilitation. Clin Rehabil 2002 Sep;16(6):617-624. [doi: 10.1191/0269215502cr530oa] [Medline: 12392336]

37. Whittaker R, McRobbie H, Bullen C, Rodgers A, Gu Y. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev 2016;4:CD006611. [doi: 10.1002/14651858.CD006611.pub4] [Medline: 27060875]

38. Zuidema R, van Dulmen S, Nijhuis-van der Sanden M, Meek I, van den Ende C, Fransen J, et al. Mobile phone interventions for self-management of chronic conditions: a thematic synthesis of qualitative studies. Health Expect 2016 Apr;19(2):194-208 [FREE Full text] [doi: 10.1111/hec.12346] [Medline: 25619975]

39. Beentjes TAA, Goossens PJJ, Vermeulen H, Teerenstra S, Nijhuis-van der Sanden MWG, van Gaal BGI. E-IMR: e-health self-management enhancing program for patients with rheumatoid arthritis: explorative randomized controlled trial. BMC Health Serv Res 2018 Dec 12;18(1):962 [FREE Full text] [doi: 10.1186/s12913-018-3767-5] [Medline: 27090724]

40. Leenen LAM, Wijnen BFM, Kessels AGH, Chan H, de Kinderen RJA, Evers SMAA, et al. Effectiveness of a multicomponent self-management intervention for adults with epilepsy (ZMILE study): a randomized controlled trial. Epilepsy Behav 2018 Mar;80:259-265. [doi: 10.1016/j.yebeh.2018.01.019] [Medline: 29449140]

41. van Houft SM, Been-Dahmen JMJ, Ista E, Boeije HR. A realist review: what do nurse-led self-management interventions achieve for outpatients with a chronic condition? J Adv Nurs 2017 Jun;73(6):1255-1271. [doi: 10.1111/jan.13189] [Medline: 27754557]

42. Dwarswaa J, Bakker EJM, Boeije HR. Self-management support from the perspective of patients with a chronic condition: a thematic synthesis of qualitative studies. Health Expect 2016 Apr;19(2):194-208 [FREE Full text] [doi: 10.1111/hec.12346] [Medline: 25619975]

43. Engelen MM, van Dulmen S, Nijhuis-van der Sanden MWG, Adriaansen MJM, Vermeulen H, Bredie SJH, et al. Self-management support in cardiovascular consultations by advanced practice nurses trained in motivational interviewing: an observational study. Patient Educ Couns 2020 Jan;103(1):159-164. [doi: 10.1016/j.pec.2019.07.018] [Medline: 31362901]

44. Crutzen R, Viechtbauer W, Kotz D, Spigt M. No differential attrition was found in randomized controlled trials published in general medical journals: a meta-analysis. J Clin Epidemiol 2013 Sep;66(9):948-954. [doi: 10.1016/j.jclinepi.2013.03.019] [Medline: 23790724]

45. Kontos E, Blake KD, Chou WS, Prestin A. Predictors of eHealth usage: insights on the digital divide from the Health Information National Trends Survey 2012. J Med Internet Res 2014;16(7):e172 [FREE Full text] [doi: 10.2196/jmir.3117] [Medline: 25048379]

46. Höfer S, Benzer W, Schüssler G, von Steinbüchel N, Oldridge NB. Health-related quality of life in patients with coronary artery disease treated for angina: validity and reliability of German translations of two specific questionnaires. Qual Life Res 2003 Mar;12(2):199-212. [doi: 10.1023/a:1022272620947] [Medline: 12639066]
47. Dougherty CM, Dewhurst T, Nichol WP, Spertus J. Comparison of three quality of life instruments in stable angina pectoris: Seattle Angina Questionnaire, Short Form Health Survey (SF-36), and Quality of Life Index-Cardiac Version III. J Clin Epidemiol 1998 Jul;51(7):569-575. [doi: 10.1016/s0895-4356(98)00028-6] [Medline: 9674663]

**Abbreviations**

- **BCT**: behavior change technique
- **BMQ**: Beliefs about Medicines Questionnaire
- **CVD**: cardiovascular disease
- **eHealth**: electronic health
- **IM**: intervention mapping
- **IPAQ**: International Physical Activity Questionnaire
- **IPQ**: Illness Perception Questionnaire
- **ITT**: intention to treat
- **mHealth**: mobile health
- **PAM-13**: Patient Activation Measure
- **PPA**: per-protocol analysis
- **RCT**: randomized controlled trial
- **SE**: patient self-efficacy with a self-constructed 26-item questionnaire

© Marscha M Engelen, Sandra van Dulmen, Saskia Puijk-Hekman, Hester Vermeulen, Maria WG Nijhuis-van der Sanden, Sebastian JH Bredie, Betsie GI van Gaal. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 24.07.2020. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included.